{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:45:53Z","timestamp":1794491153328,"version":"4.9.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"DOI":"10.1038\/s41586-026-11110-5","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:02:48Z","timestamp":1789570968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inflection points and transitions in Alzheimer\u2019s disease"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-5819","authenticated-orcid":false,"given":"Bart","family":"De Strooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-5213","authenticated-orcid":false,"given":"Eric","family":"Karran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"11110_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804 (2012). This biomarker study on familial Alzheimer\u2019s disease shows the consecutive appearance of biomarkers, some many years before cognitive alterations appear.","journal-title":"N. Engl. J. Med."},{"key":"11110_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"11110_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne, V. L. et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 12, 357\u2013367 (2013).","journal-title":"Lancet Neurol."},{"key":"11110_CR4","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","volume":"31","author":"K Horie","year":"2025","unstructured":"Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 31, 2044\u20132053 (2025).","journal-title":"Nat. Med."},{"key":"11110_CR5","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","volume":"31","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist, S. et al. Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform. Nat. Med. 31, 2036\u20132043 (2025). This is an example of a recent study confirming the validity and usefulness of the pTau217 blood biomarker.","journal-title":"Nat. Med."},{"key":"11110_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw, B. J. et al. Association of Amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915\u2013924 (2019).","journal-title":"JAMA Neurol."},{"key":"11110_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"11110_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat. Genet. 54, 412\u2013436 (2022).","journal-title":"Nat. Genet."},{"key":"11110_CR9","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/s41593-024-01774-5","volume":"27","author":"MI Gabitto","year":"2024","unstructured":"Gabitto, M. I. et al. Integrated multimodal cell atlas of Alzheimer\u2019s disease. Nat. Neurosci. 27, 2366\u20132383 (2024).","journal-title":"Nat. Neurosci."},{"key":"11110_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41586-024-07606-7","volume":"632","author":"H Mathys","year":"2024","unstructured":"Mathys, H. et al. Single-cell multiregion dissection of Alzheimer\u2019s disease. Nature 632, 858\u2013868 (2024).","journal-title":"Nature"},{"key":"11110_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-023-06437-2","volume":"621","author":"SHW Scheres","year":"2023","unstructured":"Scheres, S. H. W., Ryskeldi-Falcon, B. & Goedert, M. Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature 621, 701\u2013710 (2023).","journal-title":"Nature"},{"key":"11110_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-024-07680-x","volume":"631","author":"MAG Gilbert","year":"2024","unstructured":"Gilbert, M. A. G. et al. CryoET of \u03b2-amyloid and tau within postmortem Alzheimer\u2019s disease brain. Nature 631, 913\u2013919 (2024).","journal-title":"Nature"},{"key":"11110_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.abm7285","volume":"375","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Cryo-EM structures of amyloid-\u03b2 42 filaments from human brains. Science 375, 167\u2013172 (2022).","journal-title":"Science"},{"key":"11110_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1126\/science.abp9556","volume":"381","author":"S Balusu","year":"2023","unstructured":"Balusu, S. et al. MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer\u2019s disease. Science 381, 1176\u20131182 (2023).","journal-title":"Science"},{"key":"11110_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"11110_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper, B. & Karran, E. The cellular phase of Alzheimer\u2019s disease. Cell 164, 603\u2013615 (2016).","journal-title":"Cell"},{"key":"11110_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.stem.2021.04.004","volume":"28","author":"J Mertens","year":"2021","unstructured":"Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer\u2019s patients. Cell Stem Cell 28, 1533\u20131548.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"11110_CR18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"WT Chen","year":"2020","unstructured":"Chen, W. T. et al. Spatial transcriptomics and in situ sequencing to study Alzheimer\u2019s disease. Cell 182, 976\u2013991.e19 (2020). This spatial transcriptomic study introduced the concept of tissue domains in the field of Alzheimer\u2019s disease.","journal-title":"Cell"},{"key":"11110_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-023-06120-6","volume":"618","author":"C Depp","year":"2023","unstructured":"Depp, C. et al. Myelin dysfunction drives amyloid-\u03b2 deposition in models of Alzheimer\u2019s disease. Nature 618, 349\u2013357 (2023).","journal-title":"Nature"},{"key":"11110_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2024.12.014","volume":"113","author":"MM Santisteban","year":"2025","unstructured":"Santisteban, M. M. & Iadecola, C. The pathobiology of neurovascular aging. Neuron 113, 49\u201370 (2025).","journal-title":"Neuron"},{"key":"11110_CR21","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1016\/j.cell.2025.04.006","volume":"188","author":"SS Harris","year":"2025","unstructured":"Harris, S. S. et al. Alzheimer\u2019s disease patient-derived high-molecular-weight tau impairs bursting in hippocampal neurons. Cell 188, 3775\u20133788.e21 (2025).","journal-title":"Cell"},{"key":"11110_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41593-023-01325-4","volume":"26","author":"S Calafate","year":"2023","unstructured":"Calafate, S. et al. Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer\u2019s disease. Nat. Neurosci. 26, 1021\u20131031 (2023).","journal-title":"Nat. Neurosci."},{"key":"11110_CR23","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41591-026-04393-8","volume":"32","author":"A Lu","year":"2026","unstructured":"Lu, A. et al. Microglial transitions at the A\u03b2\u2013tau inflection point associate with divergent pathways to dementia and resilience. Nat. Med. 32, 2047\u20132059 (2026).","journal-title":"Nat. Med."},{"key":"11110_CR24","doi-asserted-by":"publisher","first-page":"114216","DOI":"10.1016\/j.celrep.2024.114216","volume":"43","author":"A Mallach","year":"2024","unstructured":"Mallach, A. et al. Microglia\u2013astrocyte crosstalk in the amyloid plaque niche of an Alzheimer\u2019s disease mouse model, as revealed by spatial transcriptomics. Cell Rep. 43, 114216 (2024).","journal-title":"Cell Rep."},{"key":"11110_CR25","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/nn.2433","volume":"12","author":"E Abramov","year":"2009","unstructured":"Abramov, E. et al. Amyloid-\u03b2 as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567\u20131576 (2009).","journal-title":"Nat. Neurosci."},{"key":"11110_CR26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga, M. et al. Alzheimer\u2019s-causing mutations shift A\u03b2 length by destabilizing \u03b3-secretase\u2013A\u03b2n interactions. Cell 170, 443\u2013456.e14 (2017). This study demonstrates how mutations in presenilin destabilize the enzyme\u2013substrate interaction between \u03b3-secretase and APP.","journal-title":"Cell"},{"key":"11110_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13024-025-00832-1","volume":"20","author":"SG Fern\u00e1ndez","year":"2025","unstructured":"Fern\u00e1ndez, S. G. et al. Spectrum of \u03b3-secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes. Mol. Neurodegener. 20, 48 (2025). This cell biology study demonstrates a linear correlation between age of onset and the ratio of long to short A\u03b2 peptides.","journal-title":"Mol. Neurodegener."},{"key":"11110_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s44318-024-00057-w","volume":"43","author":"B De Strooper","year":"2024","unstructured":"De Strooper, B. & Karran, E. New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of \u03b3-secretases. EMBO J. 43, 887\u2013903 (2024).","journal-title":"EMBO J."},{"key":"11110_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nn.2858","volume":"14","author":"T Saito","year":"2011","unstructured":"Saito, T. et al. Potent amyloidogenicity and pathogenicity of A\u03b243. Nat. Neurosci. 14, 1023\u20131032 (2011).","journal-title":"Nat. Neurosci."},{"key":"11110_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1474-4422(24)00236-9","volume":"23","author":"SA Schultz","year":"2024","unstructured":"Schultz, S. A. et al. \u03b3-Secretase activity, clinical features and biomarkers of autosomal dominant Alzheimer\u2019s disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network Observational Study (DIAN-OBS). Lancet Neurol. 23, 913\u2013924 (2024).","journal-title":"Lancet Neurol."},{"key":"11110_CR31","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1126\/science.1131864","volume":"313","author":"M Meyer-Luehmann","year":"2006","unstructured":"Meyer-Luehmann, M. et al. Exogenous induction of cerebral \u03b2-amyloidogenesis is governed by agent and host. Science 313, 1781\u20131784 (2006).","journal-title":"Science"},{"key":"11110_CR32","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/brain\/awl203","volume":"129","author":"K Sleegers","year":"2006","unstructured":"Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer\u2019s dementia with cerebral amyloid angiopathy. Brain 129, 2977\u20132983 (2006).","journal-title":"Brain"},{"key":"11110_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"G Glenner","year":"1984","unstructured":"Glenner, G. & Wong, C. W. Alzheimer\u2019s disease and down syndrom: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131\u20131135 (1984).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"11110_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/360672a0","volume":"360","author":"M Citron","year":"1992","unstructured":"Citron, M. et al. Mutation of the \u03b2-amyloid precursor protein in familial Alzheimer\u2019s disease increases \u03b2-protein production. Nature 360, 672\u2013674 (1992).","journal-title":"Nature"},{"key":"11110_CR35","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega, K. G. et al. Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease. Science 330, 1774 (2010).","journal-title":"Science"},{"key":"11110_CR36","doi-asserted-by":"publisher","first-page":"21326","DOI":"10.1074\/jbc.M112.356659","volume":"287","author":"E Winkler","year":"2012","unstructured":"Winkler, E. et al. Generation of Alzheimer disease-associated amyloid \u03b242\/43 peptide by \u03b3-secretase can be inhibited directly by modulation of membrane thickness. J. Biol. Chem. 287, 21326\u201321334 (2012).","journal-title":"J. Biol. Chem."},{"key":"11110_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54779-w","volume":"15","author":"N Balig\u00e1cs","year":"2024","unstructured":"Balig\u00e1cs, N. et al. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer\u2019s disease. Nat. Commun. 15, 10634 (2024).","journal-title":"Nat. Commun."},{"key":"11110_CR38","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","volume":"22","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Microglia use TAM receptors to detect and engulf amyloid \u03b2 plaques. Nat. Immunol. 22, 586\u2013594 (2021).","journal-title":"Nat. Immunol."},{"key":"11110_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11674-z","volume":"10","author":"E Spangenberg","year":"2019","unstructured":"Spangenberg, E. et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer\u2019s disease model. Nat. Commun. 10, 3758 (2019).","journal-title":"Nat. Commun."},{"key":"11110_CR40","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1073\/pnas.0904532106","volume":"107","author":"RP Friedrich","year":"2010","unstructured":"Friedrich, R. P. et al. Mechanism of amyloid plaque formation suggests an intracellular basis of A\u03b2 pathogenicity. Proc. Natl Acad. Sci. USA 107, 1942\u20131947 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11110_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2516774123","volume":"123","author":"K Konstantoulea","year":"2026","unstructured":"Konstantoulea, K. et al. Phagocytes as plaque catalysts: human macrophages generate seeding-competent A\u03b242 fibrils with cross-seeding activity. Proc. Natl Acad. Sci. USA 123, e2516774123 (2026). This study showed that microglia-like cells are needed to seed amyloid fibrils.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11110_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41588-021-00976-y","volume":"54","author":"K de Paiva Lopes","year":"2022","unstructured":"de Paiva Lopes, K. et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat. Genet. 54, 4\u201317 (2022.","journal-title":"Nat. Genet."},{"key":"11110_CR43","doi-asserted-by":"publisher","first-page":"110961","DOI":"10.1016\/j.celrep.2022.110961","volume":"39","author":"S Kiani Shabestari","year":"2022","unstructured":"Kiani Shabestari, S. et al. Absence of microglia promotes diverse pathologies and early lethality in Alzheimer\u2019s disease mice. Cell Rep. 39, 110961 (2022).","journal-title":"Cell Rep."},{"key":"11110_CR44","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.immuni.2024.09.014","volume":"57","author":"S Kaji","year":"2024","unstructured":"Kaji, S. et al. Apolipoprotein E aggregation in microglia initiates Alzheimer\u2019s disease pathology by seeding \u03b2-amyloidosis. Immunity 57, 2651\u20132668.e12 (2024). This study showed that microglia seed amyloid plaques.","journal-title":"Immunity"},{"key":"11110_CR45","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s44321-024-00162-7","volume":"16","author":"P Preman","year":"2024","unstructured":"Preman, P. et al. APOE from astrocytes restores Alzheimer\u2019s A\u03b2-pathology and DAM-like responses in APOE deficient microglia. EMBO Mol. Med. 16, 3113\u20133141 (2024).","journal-title":"EMBO Mol. Med."},{"key":"11110_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.40048","volume":"7","author":"X Xian","year":"2018","unstructured":"Xian, X. et al. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer\u2019s disease. eLife 7, e40048 (2018).","journal-title":"eLife"},{"key":"11110_CR47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.72034","volume":"10","author":"T Pohlkamp","year":"2021","unstructured":"Pohlkamp, T. et al. NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load. eLife 10, e72034 (2021).","journal-title":"eLife"},{"key":"11110_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas, C. et al. Microglia-derived ASC specks cross seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature 552, 355\u2013361 (2017).","journal-title":"Nature"},{"key":"11110_CR49","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol. Med. 11, e11170 (2019).","journal-title":"EMBO Mol. Med."},{"key":"11110_CR50","doi-asserted-by":"publisher","first-page":"117676","DOI":"10.1016\/j.neuroimage.2020.117676","volume":"227","author":"PS Insel","year":"2021","unstructured":"Insel, P. S., Donohue, M. C., Berron, D., Hansson, O. & Mattsson-Carlgren, N. Time between milestone events in the Alzheimer\u2019s disease amyloid cascade. Neuroimage 227, 117676 (2021).","journal-title":"Neuroimage"},{"key":"11110_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann. Neurol. 59, 512\u2013519 (2006).","journal-title":"Ann. Neurol."},{"key":"11110_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"11110_CR53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023). References 52 and 53 describe phase 3 trials demonstrating that amyloid antibodies are disease-modifying.","journal-title":"JAMA"},{"key":"11110_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41593-025-02125-8","volume":"29","author":"G Albertini","year":"2026","unstructured":"Albertini, G. et al. The Alzheimer\u2019s therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia. Nat. Neurosci. 29, 100\u2013110 (2026).","journal-title":"Nat. Neurosci."},{"key":"11110_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug Discov. 21, 306\u2013318 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11110_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"11110_CR57","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. New Engl. J. Med. 380, 1408\u20131420 (2019).","journal-title":"New Engl. J. Med."},{"key":"11110_CR58","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1016\/j.cell.2022.09.033","volume":"185","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. TREM2 drives microglia response to amyloid-\u03b2 via SYK-dependent and -independent pathways. Cell 185, 4153\u20134169.e19 (2022). This study demonstrated the role of the TREM2\u2013DAP12\u2013SYK pathway in microglia in a mouse model of Alzheimer\u2019s disease.","journal-title":"Cell"},{"key":"11110_CR59","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41593-024-01600-y","volume":"27","author":"R Mancuso","year":"2024","unstructured":"Mancuso, R. et al. Xenografted human microglia display diverse transcriptomic states in response to Alzheimer\u2019s disease-related amyloid-\u03b2 pathology. Nat. Neurosci. 27, 886\u2013900 (2024). This xenograft study demonstrated the multipronged response of human microglia to amyloid plaques.","journal-title":"Nat. Neurosci."},{"key":"11110_CR60","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.immuni.2022.03.018","volume":"55","author":"ER Roy","year":"2022","unstructured":"Roy, E. R. et al. Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid \u03b2 plaques. Immunity 55, 879\u2013894.e6 (2022).","journal-title":"Immunity"},{"key":"11110_CR61","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1016\/j.immuni.2025.07.024","volume":"58","author":"Z Song","year":"2025","unstructured":"Song, Z. et al. Innate immune sensing of Z-nucleic acids by ZBP1\u2013RIPK1 axis drives neuroinflammation in Alzheimer\u2019s disease. Immunity 58, 2574\u20132592.e9 (2025).","journal-title":"Immunity"},{"key":"11110_CR62","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-021-03734-6","volume":"595","author":"CS McAlpine","year":"2021","unstructured":"McAlpine, C. S. et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer\u2019s disease. Nature 595, 701\u2013706 (2021).","journal-title":"Nature"},{"key":"11110_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41593-025-02103-0","volume":"29","author":"JP Ferrari-Souza","year":"2026","unstructured":"Ferrari-Souza, J. P. et al. Microglia modulate A\u03b2-dependent astrocyte reactivity in Alzheimer\u2019s disease. Nat. Neurosci. 29, 81\u201387 (2026).","journal-title":"Nat. Neurosci."},{"key":"11110_CR64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017). This single-cell study focused on the identification of reactive astrocytes in Alzheimer\u2019s disease.","journal-title":"Nature"},{"key":"11110_CR65","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib, N. et al. Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat. Neurosci. 23, 701\u2013706 (2020).","journal-title":"Nat. Neurosci."},{"key":"11110_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/alz.13387","volume":"20","author":"S Das","year":"2024","unstructured":"Das, S. et al. Distinct transcriptomic responses to A\u03b2 plaques, neurofibrillary tangles, and APOE in Alzheimer\u2019s disease. Alzheimers Dement. 20, 74\u201390 (2024).","journal-title":"Alzheimers Dement."},{"key":"11110_CR67","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/s41588-024-01961-x","volume":"56","author":"E Miyoshi","year":"2024","unstructured":"Miyoshi, E. et al. Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer\u2019s disease. Nat. Genet. 56, 2704\u20132717 (2024).","journal-title":"Nat. Genet."},{"key":"11110_CR68","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41586-024-07871-6","volume":"633","author":"GS Green","year":"2024","unstructured":"Green, G. S. et al. Cellular communities reveal trajectories of brain ageing and Alzheimer\u2019s disease. Nature 633, 634\u2013645 (2024).","journal-title":"Nature"},{"key":"11110_CR69","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","volume":"62","author":"S Li","year":"2009","unstructured":"Li, S. et al. Soluble oligomers of amyloid \u03b2\u00a0protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788\u2013801 (2009).","journal-title":"Neuron"},{"key":"11110_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111280","volume":"40","author":"D Shah","year":"2022","unstructured":"Shah, D. et al. Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer\u2019s disease. Cell Rep. 40, 111280 (2022). This study demonstrated that hypoactivity in astrocytes leads to hyperactivity in neurons in Alzheimer\u2019s disease.","journal-title":"Cell Rep."},{"key":"11110_CR71","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.cell.2012.02.046","volume":"149","author":"L Verret","year":"2012","unstructured":"Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in alzheimer model. Cell 149, 708\u2013721 (2012).","journal-title":"Cell"},{"key":"11110_CR72","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41593-018-0080-x","volume":"21","author":"B Styr","year":"2018","unstructured":"Styr, B. & Slutsky, I. Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer\u2019s disease. Nat. Neurosci. 21, 463\u2013473 (2018). This perspective highlights the critical role of homeostatic plasticity and its progressive decline in the development of Alzheimer\u2019s disease.","journal-title":"Nat. Neurosci."},{"key":"11110_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neuron.2017.11.028","volume":"97","author":"S Frere","year":"2018","unstructured":"Frere, S. & Slutsky, I. Alzheimer\u2019s disease: from firing instability to homeostasis network collapse. Neuron 97, 32\u201358 (2018).","journal-title":"Neuron"},{"key":"11110_CR74","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","volume":"65","author":"B Dickerson","year":"2005","unstructured":"Dickerson, B. et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404\u2013411 (2005).","journal-title":"Neurology"},{"key":"11110_CR75","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","volume":"70","author":"KA Vossel","year":"2013","unstructured":"Vossel, K. A. et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158\u20131166 (2013).","journal-title":"JAMA Neurol."},{"key":"11110_CR76","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamaneurol.2025.1734","volume":"82","author":"SK Rohde","year":"2025","unstructured":"Rohde, S. K. et al. Amyloid-beta pathology and cognitive performance in centenarians. JAMA Neurol. 82, 837\u2013847 (2025).","journal-title":"JAMA Neurol."},{"key":"11110_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/brain\/awae325","volume":"148","author":"GG Kovacs","year":"2025","unstructured":"Kovacs, G. G. et al. Amyloid-\u03b2 predominant Alzheimer\u2019s disease neuropathologic change. Brain 148, 401\u2013407 (2025).","journal-title":"Brain"},{"key":"11110_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40478-023-01530-z","volume":"11","author":"C Mu\u00f1oz-Castro","year":"2023","unstructured":"Mu\u00f1oz-Castro, C. et al. Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer\u2019s disease hippocampus. Acta Neuropathol. Commun. 11, 31 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"11110_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70502","volume":"21","author":"M Fern\u00e1ndez-Matarrubia","year":"2025","unstructured":"Fern\u00e1ndez-Matarrubia, M. et al. Early microglial and astrocyte reactivity in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 21, e70502 (2025).","journal-title":"Alzheimers Dement."},{"key":"11110_CR80","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298.e7 (2018).","journal-title":"Neuron"},{"key":"11110_CR81","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.aeb6987","volume":"392","author":"B De Strooper","year":"2026","unstructured":"De Strooper, B. & Zetterberg, H. Tracking the turning point in Alzheimer\u2019s disease. Science 392, 468\u2013469 (2026).","journal-title":"Science"},{"key":"11110_CR82","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e17123 (2023).","journal-title":"EMBO Mol. Med."},{"key":"11110_CR83","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","volume":"20","author":"PM Cogswell","year":"2024","unstructured":"Cogswell, P. M. et al. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimers Dement. 20, 1225\u20131238 (2024).","journal-title":"Alzheimers Dement."},{"key":"11110_CR84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 78, 149\u2013156 (2021).","journal-title":"JAMA Neurol."},{"key":"11110_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70320","volume":"21","author":"C Lane-Donovan","year":"2025","unstructured":"Lane-Donovan, C. et al. Tau phosphorylation at Alzheimer\u2019s disease biomarker sites impairs its cleavage by lysosomal proteases. Alzheimers Dement. 21, e70320 (2025).","journal-title":"Alzheimers Dement."},{"key":"11110_CR86","volume":"13","author":"S L\u00f6vestam","year":"2025","unstructured":"L\u00f6vestam, S. et al. Twelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filaments. eLife 13, RP104778 (2025). This study demonstrated that 12 phosphomimetic substitutions are sufficient to induce the Alzheimer\u2019s fold in tau.","journal-title":"eLife"},{"key":"11110_CR87","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.neurobiolaging.2013.03.015","volume":"34","author":"T Rodr\u00edguez-Mart\u00edn","year":"2013","unstructured":"Rodr\u00edguez-Mart\u00edn, T. et al. Tau phosphorylation affects its axonal transport and degradation. Neurobiol. Aging 34, 2146\u20132157 (2013).","journal-title":"Neurobiol. Aging"},{"key":"11110_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12692","volume":"17","author":"B Caballero","year":"2018","unstructured":"Caballero, B. et al. Interplay of pathogenic forms of human tau with different autophagic pathways. Aging Cell 17, e12692 (2018).","journal-title":"Aging Cell"},{"key":"11110_CR89","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190 (2017). Structural studies resolved an Alzheimer\u2019s disease-specific fold in tau at atomic resolution.","journal-title":"Nature"},{"key":"11110_CR90","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1021\/bi0521543","volume":"45","author":"S Jeganathan","year":"2006","unstructured":"Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H.-J. & Mandelkow, E. Global hairpin folding of tau in solution. Biochemistry 45, 2283\u20132293 (2006).","journal-title":"Biochemistry"},{"key":"11110_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000034","volume":"7","author":"MD Mukrasch","year":"2009","unstructured":"Mukrasch, M. D. et al. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol. 7, e34 (2009).","journal-title":"PLoS Biol."},{"key":"11110_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64312-2","volume":"16","author":"A Kasen","year":"2025","unstructured":"Kasen, A. et al. Seed structure and phosphorylation in the fuzzy coat impact tau seeding competency. Nat. Commun. 16, 9240 (2025).","journal-title":"Nat. Commun."},{"key":"11110_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00401-025-02930-2","volume":"150","author":"WS Brum","year":"2025","unstructured":"Brum, W. S. et al. Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study. Acta Neuropathol. 150, 36 (2025).","journal-title":"Acta Neuropathol."},{"key":"11110_CR94","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf221","volume":"7","author":"F Gonzalez-Ortiz","year":"2025","unstructured":"Gonzalez-Ortiz, F. et al. The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer\u2019s disease. Brain Commun. 7, fcaf221 (2025).","journal-title":"Brain Commun."},{"key":"11110_CR95","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183, 1699\u20131713.e13 (2020). This was a landmark study on the post-translational modifications of tau.","journal-title":"Cell"},{"key":"11110_CR96","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","volume":"24","author":"J Therriault","year":"2025","unstructured":"Therriault, J. et al. Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 24, 740\u2013752 (2025).","journal-title":"Lancet Neurol."},{"key":"11110_CR97","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.celrep.2025.116203","volume":"44","author":"Y Hirota","year":"2025","unstructured":"Hirota, Y. et al. Biomarker-related phospho-tau217 appears in synapses around A\u03b2 plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer\u2019s disease. Cell Rep. 44, 116203 (2025).","journal-title":"Cell Rep."},{"key":"11110_CR98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40478-021-01307-2","volume":"10","author":"M Wennstr\u00f6m","year":"2022","unstructured":"Wennstr\u00f6m, M. et al. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathol. Commun. 10, 3 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"11110_CR99","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00401-019-02046-4","volume":"138","author":"VI Wiersma","year":"2019","unstructured":"Wiersma, V. I. et al. Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology. Acta Neuropathol. 138, 943\u2013970 (2019).","journal-title":"Acta Neuropathol."},{"key":"11110_CR100","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00401-011-0871-6","volume":"122","author":"DR Thal","year":"2011","unstructured":"Thal, D. R. et al. Stages of granulovacuolar degeneration: their relation to Alzheimer\u2019s disease and chronic stress response. Acta Neuropathol. 122, 577\u2013589 (2011).","journal-title":"Acta Neuropathol."},{"key":"11110_CR101","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-019-02103-y","volume":"139","author":"MJ Koper","year":"2020","unstructured":"Koper, M. J. et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer\u2019s disease. Acta Neuropathol. 139, 463\u2013484 (2020). This neuropathology study demonstrated the presence of necrosomes in hippocampal neurons from patients with Alzheimer\u2019s disease.","journal-title":"Acta Neuropathol."},{"key":"11110_CR102","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","volume":"143","author":"SA Kaeser","year":"2022","unstructured":"Kaeser, S. A. et al. CSF p-tau increase in response to A\u03b2-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287\u2013290 (2022).","journal-title":"Acta Neuropathol."},{"key":"11110_CR103","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41593-024-01829-7","volume":"28","author":"N Watamura","year":"2025","unstructured":"Watamura, N. et al. In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds. Nat. Neurosci. 28, 293\u2013307 (2025).","journal-title":"Nat. Neurosci."},{"key":"11110_CR104","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1074\/jbc.RA119.009487","volume":"294","author":"T Saito","year":"2019","unstructured":"Saito, T. et al. Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J. Biol. Chem. 294, 12754\u201312765 (2019).","journal-title":"J. Biol. Chem."},{"key":"11110_CR105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00401-025-02943-x","volume":"150","author":"TE Richardson","year":"2025","unstructured":"Richardson, T. E. et al. Primary age-related tauopathy. Acta Neuropathol. 150, 40 (2025).","journal-title":"Acta Neuropathol."},{"key":"11110_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu, L. et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 146, 1\u201311 (2023).","journal-title":"Acta Neuropathol."},{"key":"11110_CR107","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1021\/acschemneuro.1c00454","volume":"12","author":"DC Rodriguez Camargo","year":"2021","unstructured":"Rodriguez Camargo, D. C. et al. Proliferation of tau 304\u2013380 fragment aggregates through autocatalytic secondary nucleation. ACS Chem. Neurosci. 12, 4406\u20134415 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"11110_CR108","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci. Adv. 6, eaaz2387 (2020).","journal-title":"Sci. Adv."},{"key":"11110_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14482","volume":"21","author":"A Benussi","year":"2025","unstructured":"Benussi, A. et al. Plasma p-tau217 and neurofilament\/p-tau217 ratio in differentiating Alzheimer\u2019s disease from syndromes associated with frontotemporal lobar degeneration. Alzheimers Dement. 21, e14482 (2025).","journal-title":"Alzheimers Dement."},{"key":"11110_CR110","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/acn3.51435","volume":"8","author":"C Sato","year":"2021","unstructured":"Sato, C. et al. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. Ann. Clin. Transl. Neurol. 8, 1817\u20131830 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"11110_CR111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He, Z. et al. Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 24, 29\u201338 (2018).","journal-title":"Nat. Med."},{"key":"11110_CR112","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","volume":"73","author":"A De Calignon","year":"2012","unstructured":"De Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer\u2019s disease. Neuron 73, 685\u2013697 (2012).","journal-title":"Neuron"},{"key":"11110_CR113","doi-asserted-by":"publisher","first-page":"107313","DOI":"10.1016\/j.jbc.2024.107313","volume":"300","author":"JM Cooper","year":"2024","unstructured":"Cooper, J. M. et al. SORL1 is a receptor for tau that promotes tau seeding. J. Biol. Chem. 300, 107313 (2024).","journal-title":"J. Biol. Chem."},{"key":"11110_CR114","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085\u20131092 (2016).","journal-title":"Nat. Neurosci."},{"key":"11110_CR115","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.celrep.2015.04.043","volume":"11","author":"S Calafate","year":"2015","unstructured":"Calafate, S. et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 11, 1176\u20131183 (2015).","journal-title":"Cell Rep."},{"key":"11110_CR116","doi-asserted-by":"publisher","first-page":"e31302","DOI":"10.1371\/journal.pone.0031302","volume":"7","author":"L Liu","year":"2012","unstructured":"Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 7, e31302 (2012). References 112, 115 and 116 revealed and characterized trans-synaptic propagation of tau.","journal-title":"PLoS One"},{"key":"11110_CR117","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards, A. L. et al. Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 80, 1344\u20131352 (2023).","journal-title":"JAMA Neurol."},{"key":"11110_CR118","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","volume":"16","author":"T G\u00f3mez-Isla","year":"1996","unstructured":"G\u00f3mez-Isla, T. et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer\u2019s disease. J. Neurosci. 16, 4491\u20134500 (1996).","journal-title":"J. Neurosci."},{"key":"11110_CR119","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","volume":"58","author":"JL Price","year":"2001","unstructured":"Price, J. L. et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58, 1395\u20131402 (2001).","journal-title":"Arch. Neurol."},{"key":"11110_CR120","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1982","unstructured":"Whitehouse, P. J. et al. Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237\u20131239 (1982).","journal-title":"Science"},{"key":"11110_CR121","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jalz.2016.06.2362","volume":"13","author":"P Theofilas","year":"2017","unstructured":"Theofilas, P. et al. Locus coeruleus volume and cell population changes during Alzheimer\u2019s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 13, 236\u2013246 (2017).","journal-title":"Alzheimers Dement."},{"key":"11110_CR122","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann. Neurol. 27, 457\u2013464 (1990).","journal-title":"Ann. Neurol."},{"key":"11110_CR123","doi-asserted-by":"publisher","first-page":"115758","DOI":"10.1016\/j.celrep.2025.115758","volume":"44","author":"G Lin","year":"2025","unstructured":"Lin, G. et al. Cell-death pathways and tau-associated neuronal vulnerability in Alzheimer\u2019s disease. Cell Rep. 44, 115758 (2025).","journal-title":"Cell Rep."},{"key":"11110_CR124","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nn.4608","volume":"20","author":"A Caccamo","year":"2017","unstructured":"Caccamo, A. et al. Necroptosis activation in Alzheimer\u2019s disease. Nat. Neurosci. 20, 1236\u20131246 (2017).","journal-title":"Nat. Neurosci."},{"key":"11110_CR125","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature14191","volume":"517","author":"M Pasparakis","year":"2015","unstructured":"Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311\u2013320 https:\/\/doi.org\/10.1038\/nature14191 (2015).","journal-title":"Nature"},{"key":"11110_CR126","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00005072-196201000-00007","volume":"21","author":"JS Woodard","year":"1962","unstructured":"Woodard, J. S. Clinicopathologic significance of granulovacuolar degeneration in Alzheimer\u2019s disease. J. Neuropathol. Exp. Neurol. 21, 85\u201391 (1962).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"11110_CR127","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-022-02528-y","volume":"145","author":"S Moonen","year":"2023","unstructured":"Moonen, S. et al. Pyroptosis in Alzheimer\u2019s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 145, 175\u2013195 (2023).","journal-title":"Acta Neuropathol."},{"key":"11110_CR128","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"11110_CR129","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaneurol.2025.2974","volume":"82","author":"PS Insel","year":"2025","unstructured":"Insel, P. S. et al. Concurrent changes in plasma phosphorylated Tau 217, Tau PET, and cognition in preclinical Alzheimer disease. JAMA Neurol. 82, 985\u2013993 (2025).","journal-title":"JAMA Neurol."},{"key":"11110_CR130","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.stem.2015.09.001","volume":"17","author":"J Mertens","year":"2015","unstructured":"Mertens, J. et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell 17, 705\u2013718 (2015).","journal-title":"Cell Stem Cell"},{"key":"11110_CR131","doi-asserted-by":"crossref","unstructured":"Ganz, A. B. et al. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol. Commun. 6, 64 (2018).","DOI":"10.1186\/s40478-018-0558-5"},{"key":"11110_CR132","doi-asserted-by":"crossref","unstructured":"Zhang, M. et al. The correlation between neuropathology levels and cognitive performance in centenarians. Alzheimers Dement. 19, 5036\u20135047 (2023).","DOI":"10.1002\/alz.13087"},{"key":"11110_CR133","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680\u20131683 (2019).","journal-title":"Nat. Med."},{"key":"11110_CR134","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.abb8575","volume":"370","author":"A Sierksma","year":"2020","unstructured":"Sierksma, A., Escott-Price, V. & De Strooper, B. Translating genetic risk of Alzheimer\u2019s disease into mechanistic insight and drug targets. Science 370, 61\u201366 (2020).","journal-title":"Science"},{"key":"11110_CR135","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann, S. et al. The TREM2\u2013APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566\u2013581.e9 (2017).","journal-title":"Immunity"},{"key":"11110_CR136","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169, 1276\u20131290.e17 (2017).","journal-title":"Cell"},{"key":"11110_CR137","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","volume":"615","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature 615, 668\u2013677 (2023).","journal-title":"Nature"},{"key":"11110_CR138","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"D Gate","year":"2020","unstructured":"Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature 577, 399\u2013404 (2020).","journal-title":"Nature"},{"key":"11110_CR139","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/brain\/awad309","volume":"147","author":"IJ Hartnell","year":"2024","unstructured":"Hartnell, I. J. et al. Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology. Brain 147, 590\u2013606 (2024).","journal-title":"Brain"},{"key":"11110_CR140","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000486200","volume":"18","author":"M Merlini","year":"2018","unstructured":"Merlini, M., Kirabali, T., Kulic, L., Nitsch, R. M. & Ferretti, M. T. Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. Neurodegener. Dis. 18, 49\u201356 (2018).","journal-title":"Neurodegener. Dis."},{"key":"11110_CR141","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41590-023-01604-z","volume":"24","author":"W Su","year":"2023","unstructured":"Su, W. et al. CXCR6 orchestrates brain CD8+ T cell residency and limits mouse Alzheimer\u2019s disease pathology. Nat. Immunol. 24, 1735\u20131747 (2023).","journal-title":"Nat. Immunol."},{"key":"11110_CR142","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","volume":"48","author":"V Dor\u00e9","year":"2021","unstructured":"Dor\u00e9, V. et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur. J. Nucl. Med. Mol. Imaging 48, 2225\u20132232 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"11110_CR143","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimers Dement."},{"key":"11110_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70662","volume":"21","author":"R Yaari","year":"2025","unstructured":"Yaari, R. et al. Donanemab in preclinical Alzheimer\u2019s disease: screening and baseline data from TRAILBLAZER-ALZ 3. Alzheimers Dement. 21, e70662 (2025).","journal-title":"Alzheimers Dement."},{"key":"11110_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-026-02036-1","author":"CE Cohen","year":"2026","unstructured":"Cohen, C. E. et al. Genetic drivers of progression in Alzheimer\u2019s disease are distinct from disease risk. Alzheimers Res. Ther. https:\/\/doi.org\/10.1186\/s13195-026-02036-1 (2026).","journal-title":"Alzheimers Res. Ther."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11110-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:03:10Z","timestamp":1794405790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":145,"alternative-id":["11110"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-11110-5","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.D.S. is a consultant for several pharmaceutical and biotech companies, scientific founder of Muna TX and Augustine TX and a minor share holder of Muna Tx. E.K. is a consultant for several pharmaceutical, biotech and venture capital companies and founder of Vannin Pharma Consulting LLC.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}